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Expert Commentaries Gardner and O’GaraThe Cardiothoracic Surgery Network: Randomized clinical trials in
the operating roomTimothy J. Gardner, MD,a and Patrick T. O’Gara, MDbIn 2006, the National Heart, Lung, and Blood Institute
(NHLBI) announced the formation of a new clinical research
network titled, ‘‘The Network for Cardiothoracic Surgical
Investigations in Cardiovascular Medicine.’’1 Numerous aca-
demic cardiac surgery groups in the United States and Canada
submitted applications. There were additional applications
from clinical research organizations to serve as the network’s
Data Coordinating Center (DCC). Seven clinical sites in the
United States and 1 in Canada were selected for participation
in the network, along with a DCC (see Appendix). Notifica-
tion of awards was made in July 2007 and network activity
began soon thereafter. The network has recently expanded
to include additional enrolling sites (Appendix).
The goal of the Cardiothoracic Surgery Network (CTSN)
is to establish a cooperative network of cardiac surgery pro-
grams to promulgate the use of evidence-based medicine in
surgical practice. CTSN is intended to conduct important,
randomized clinical trials and observational studies, dissem-
inate the results, and thereby translate the findings into clin-
ical practice. The program is expected to support and
maintain the necessary infrastructure to develop, coordinate,
and conduct several collaborative clinical studies and inter-
ventional protocols designed to improve cardiovascular dis-
ease outcomes. Participating sites are required to provide
adequate patient populations, foster a culture of clinical re-
search, and support the infrastructure necessary for success-
ful patient enrollment and study completion. The network’s
DCC provides the organizational expertise for conduct of
the trials across the sites, while managing network opera-
tions. The purpose of this short report is to publicize the
organizational administration and projects currently under
study.
There is a Steering Committee (SC) that includes the prin-
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gram officers. Two external committees appointed by the
NHLBI are the Protocol Review Committee and the Data
and Safety Monitoring Board. There is also an Event Adju-
dication Committee. Core laboratories are established, as
needed, for specific trials and are subcontracted by the
DCC. Examples include echocardiography, cardiopulmo-
nary exercise testing, and ambulatory rhythm monitoring.
Subcommittees of the SC manage network policies and
functions, such as budget and publications.
DEVELOPMENT OF TRIAL PROTOCOLS
At the inaugural meeting of the SC in September 2007, the
principal investigators reviewed multiple proposals for net-
work trials. There was consensus around the issue of optimal
management of patients with ischemic heart disease and mi-
tral regurgitation (MR). Another area of consensus focused
on concomitant atrial fibrillation (AF) ablation procedures
for patients undergoing mitral valve surgery (MVS).
Committees were then established to develop the clinical
trial protocols. These protocol development committees
typically meet weekly by teleconference. Protocols are re-
fined through biweekly SC teleconferences and 3 times per
year in-person SC meetings that include co-investigators.
Study coordinators, key members of the research teams
who are responsible for patient screening, enrollment, and
data collection, also meet regularly by teleconference and
participate in the in-person SC meetings.
Network protocols progress through many steps in devel-
opment and refinement through the protocol development
committees. Iterative drafts of the protocol are brought to
the full SC for approval. Once approved, the protocol is re-
viewed and amended, as needed, by the independent Proto-
col Review Committee. For a protocol that involves a drug
or medical device, such as a tissue ablation device for AF
procedures, additional approval by the US Food and Drug
Administration is required. After network Data and Safety
Monitoring Board review, the study protocol requires
approval by the DCC’s Institutional Review Board. Each
clinical site then submits the protocol to its own institutional
review board for approval. Throughout the many steps in
this process, NHLBI program officers are engaged and
provide final approval for the studies.
SURGICAL INTERVENTIONS FOR MODERATE
ISCHEMIC MR
This trial is designed to study 300 patients with coronary
artery disease and moderate ischemic MR (IMR). Theery c April 2010
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(CABG) plus mitral valve repair using an undersized annu-
loplasty ring or to CABG alone. The primary end point is the
degree of left ventricular remodeling as assessed by a change
in left ventricular end-systolic volume index at 12 months.
Additional secondary end points include various clinical
outcomes at 6, 12, and 24 months, other echocardiographic
outcomes, functional status, quality of life, and neurocogni-
tive outcomes.
The target population is patients with moderate IMR re-
ferred for CABG. CTSN investigators identified a lack of
consensus as to optimal therapy for moderate IMR and the
degree to which CABG alone will improve MR and ventric-
ular function. IMR is not a structural valve problem. It is
characterized by geometric alterations of the left ventricle
that may be global or regional. Although both regional and
global changes may respond to revascularization, the degree
to which revascularization alone can stabilize or reverse as-
sociated MR is unpredictable.2-7
For patients with IMR treated with CABG alone, the
unadjusted incidence of death is increased with moderate
IMR and is increased even in the presence of only mild
IMR compared with patients with no IMR.8 Patients
with IMR may also have other significant adverse events,
such as progressive heart failure and the need for reinter-
vention.
Available evidence addressing treatment decisions for
patients with IMR is limited to observational studies and
case series, in which correction for significant and substan-
tial imbalances in baseline patient characteristics and selec-
tion bias may be lacking. Furthermore, American College of
Cardiology/American Heart Association guidelines for
CABG and valve disease do not provide a decision algo-
rithm for IMR. The indication for mitral valve operation
in the patient who undergoes CABG with mild to moderate
MR is still unclear, although there are data to indicate ben-
efit of mitral valve repair in some patients with moderate
IMR.9 What is clear from many reports of patients with
coronary artery disease and IMR is that their prognosis is
poorer than that of patients with coronary artery disease
alone, regardless of treatment, and that a randomized clini-
cal trial should prove helpful to clinicians managing such
patients.
Patients with primary structural mitral valve defects are
excluded as are patients in cardiogenic shock. Inclusion in
this trial requires a patient to meet specific echocardio-
graphic criteria. On transthoracic examination, the quanti-
tative parameter for MR to qualify as moderate is an
effective regurgitant orifice area between 0.2 and 0.39
cm2. If the effective regurgitant orifice area is less than
0.2 cm2, the degree of regurgitation can be judged as
moderate using other quantitative and integrative criteria,
as recommended by the American Society of Echocardi-
ography.10The Journal of Thoracic and CaEVALUATION OF OUTCOMES AFTER MITRAL
VALVE REPAIR OR REPLACEMENT IN SEVERE
ISCHEMIC MR
The objective of this study is to evaluate the safety and ef-
ficacy of mitral valve repair versus valve replacement for pa-
tients with severe IMR. A total of 250 patients with coronary
artery disease and severe IMR are being randomized 1:1 to
mitral valve repair or replacement with or without surgical
revascularization. The primary end point is change in left
ventricular end-systolic volume index at 12 months. Addi-
tional secondary end points include clinical outcomes at 6,
12, and 24 months, other echocardiographic outcomes, func-
tional status, quality of life assessment, and neurocognitive
outcomes. Severe MR is defined echocardiographically by
an effective regurgitant orifice area greater than 0.4 cm2 or
by using the integrative criteria recommended by the Amer-
ican Society of Echocardiography.10
Severe IMR is associated with very poor health outcomes in
patients with cardiac disease. As a complication of myocardial
infarction, IMR has a poor prognosis with a 5-year survival of
only about 30% in the presence of severe MR.11 Several stud-
ies have compared replacement with repair in patients with se-
vere MR, but uncertainty persists regarding the optimal
surgical approach for these patients. As with the management
of patients with moderate IMR, available evidence is limited
to observational studies and case series. There are several
reports of effective early valve repair followed by late repair
failure and recurrence of severe MR. Given the increasing
prevalence of this high-mortality condition and apparent
equipoise among surgeons as to preferred operative
treatment,6,7,12,13 the SC concluded that a randomized study
was needed. This trial of valve repair versus replacement is
addressing the effectiveness of valve repair that includes,
when necessary, a subvalvular procedure to deal with severe
tethering versus mitral valve replacement with complete
preservation of the subvalvular apparatus.SURGICAL ABLATION VERSUS NO SURGICAL
ABLATION FOR PATIENTSWITH PERSISTENTAF
UNDERGOING MVS
This trial is designed to enroll 260 patients with chronic
AF and mitral valve disease requiring surgery. The patients
will be randomized in 1:1 fashion to MVS with an ablation
procedure plus left atrial appendage ligation or MVS with
left atrial appendage ligation alone. Patients in the ablation
treatment group will be further randomized to pulmonary
vein isolation alone or to pulmonary vein isolation and a bia-
trial lesion set. The primary end point is freedom from AF at
both 6 and 12 months. Additional secondary end points in-
clude clinical outcomes at 6, 12, and 24 months, functional
status, and quality of life assessment.
New tissue ablation technologies have resulted in many
more attempts at AF ablation during heart surgery. Theserdiovascular Surgery c Volume 139, Number 4 831
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and have reduced operative times substantially. Most current
procedures include pulmonary vein isolation with or without
additional lesions sets in the left atrium; in most cases, the
right atrium is left untreated. These simpler ablation proce-
dures compared with the complex Cox maze II operation
have led to an increase in surgical ablations performed
over the past 5 years. MVS patients represent the majority
of those treated.
Although surgical pulmonary vein isolation is the most
common approach currently, there is evidence that more ex-
tensive lesion sets may increase ablation effectiveness. In the
electrophysiology laboratory, higher rates of freedom from
AF correlate with a greater volume of ablated left atrial tis-
sue. On the basis of these reports, an ablation procedure
that includes a connecting lesion to the mitral annulus and
right atrial lesions may be more effective than simple pulmo-
nary vein isolation alone.
Ablation procedure success generally is defined by free-
dom from AF at 12 months. Assessment of the absence of
AF, however, can be challenging, with the accuracy of AF
detection dependent on the tracking methods used. The pri-
mary end point of this study will be freedom from AF using
3-day continuous monitoring at 6 and 12 months after abla-
tion. In addition, weekly rhythm strips will be collected to
assess AF load. This strategy of intense rhythm monitoring
using 2 different techniques will enable the investigators to
compare the effectiveness of these 2 methods of AF ablation,
providing important guidance for the design of future trials.
Before undertaking a large-scale, pivotal trial to assess the
clinical benefit of surgical ablation for AF in patients under-
going MVS, the network is undertaking this proof-of-
concept trial to demonstrate the sustained effectiveness of
surgical ablation and to guide the choice of ablation proce-
dure. Inasmuch as the left atrium is already opened for
MVS, the ablation procedure will add little time and risk.
If ablation is effective over MVS alone, subsequent trials
can compare specific lesion sets and ablation devices.
CTSN OBSERVATIONAL STUDIES
1. Management Practices and the Risk of Infections
After Cardiac Surgery
The objective of this short-term observational study is the
identification of modifiable management practices and pa-
tient characteristics that are predictive of postoperative in-
fections. In addition, the study is designed to delineate
practice variations that may be associated with higher infec-
tion rates. Patients will be monitored for 60 days after the in-
dex cardiac surgical intervention and the enrollment period
will continue until a minimum of 200 patients with major in-
fections are accrued. This study is expected to require up to
a 6-month enrollment period.
Hospital-acquired infections represent the main noncar-
diac complication after heart surgery. They are associated832 The Journal of Thoracic and Cardiovascular Surgwith substantial morbidity and higher mortality. In addition,
infectious complications result in greater economic burden.
This observational study will allow for an assessment of how
major infections and the management practices associated
with their occurrence affect patient outcomes as well as hos-
pital resource use and inpatient costs.
2. Planning Grant to Compare Hybrid
Revascularization With Percutaneous Coronary
Intervention for Patients With Multivessel Coronary
Artery Disease
This multicenter observational study is funded separately
by NHLBI as a National Institutes of Health Challenge
Grant in Health and Science Research.14 It was awarded in
September 2009 to a consortium of CTSN investigators
and several other cardiac surgery groups. The objective of
this study is to explore relevant aspects of hybrid coronary
revascularization (HCR) and to compare HCR to multivessel
percutaneous coronary intervention (PCI) to design a pivotal
comparative effectiveness trial of this emerging therapeutic
strategy. HCR involves the surgical placement, generally
without use of cardiopulmonary bypass, of a left internal
thoracic artery bypass graft to an obstructed left anterior
descending artery, along with concomitant PCI to other
obstructed coronary arteries. A specific aim of this observa-
tional study includes characterization of the patients
currently undergoing HCR to address the feasibility of re-
cruitment of this target population into a clinical trial. In
addition, this study will track event rates in patients with
multivessel coronary revascularization undergoing HCR or
PCI. Management practices for HCR and PCI procedures
will be observed, along with concomitant medical therapies
and the variations within and among participating institu-
tions, with the goal of developing a definitive clinical trial
subsequent to this observational period.
Two patient cohorts will be enrolled in this study. The first
group will be identified during the initial 3-month period
when undergoing coronary angiography. The second group
will be enrolled over a 12-month period when they undergo
an HCR or multivessel PCI procedure. All enrolled patients
will be monitored for a minimum of 18 months. To date,
there has been no randomized trial comparing HCR with ei-
ther CABG or PCI. Preliminary observational data suggest
that HCR has the potential to disseminate widely and be-
come the third major interventional alternative for patients
with multivessel coronary artery disease. Without sound
data from a randomized clinical trial, there may be insuffi-
cient evidence to guide application of this potentially impor-
tant procedure for a major patient population.
SUMMARY
At the midpoint in its initial 5-year funding period, the
CTSN has successfully undertaken several multicenter ran-
domized trials involving patients undergoing heart surgery.ery c April 2010
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year in the randomized trials involving MVS. Patients with
persistent AF having MVS are now being enrolled in a trial
examining the effectiveness of concurrent AF ablation pro-
cedures. Both of the observational studies, just described,
have commenced. The HCR project comparing hybrid re-
vascularization and PCI, undertaken through supplemental
funding as an NIH Challenge Grant, has allowed the
CTSN to engage additional cardiac surgery centers in this in-
novative research study.
The enrollment of patients who are undergoing major car-
diac surgery in trials that involve randomization to different
operative techniques historically has been challenging.
Skeptics claim that randomized trials of surgery patients
are impossible to complete successfully. Others question
whether cardiac surgeons can accept the concept of equi-
poise or are willing to address uncertainty about optimal
treatment with their patients. This early experience with
CTSN refutes such skepticism. Patient enrollment, however,
remains challenging. Commitment to patient screening and
enrollment in these trials must be made by all physicians
who care for eligible patients, including the cardiologists
at the clinical centers. The principal requirement, however,
remains the acceptance by the operating surgeon that equi-
poise is present and that evidence of procedural effective-
ness based on outcomes must be pursued. Additional
information regarding the CTSN can be found at http://
www.ctsurgerynet.org/.
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Cardiothoracic Surgical InvestigationsCore Clinical Centers (Principal Investigator)
Cleveland Clinical Foundation (Eugene H. Blackstone,
MD)
Columbia University Medical Center (Michael Argen-
ziano, MD)
Duke University (Peter K. Smith, MD)
Emory University (John D. Puskas, MD)
Montefiore Medical Center–Albert Einstein College of
Medicine (Robert E. Michler, MD)
Montreal Heart Institute (Louis P. Perrault, MD)
University of Pennsylvania (Michael A. Acker, MD)
University of Virginia Health Systems (Irving L. Kron, MD)
Affiliated and Ancillary Clinical Centers (Principal
Investigator)
Centre Hospitalier de l’Universite´ de Montre´al (Nicolas
Noiseux, MD)
East Carolina Heart Institute (T. Bruce Ferguson, MD)Hoˆpital du Sacre´-Coeur de Montre´al (Pierre Page´, MD)
Inova Heart & Vascular Institute, Fairfax, Va (Alan M.
Speir, MD)
Institut Universitaire de Cardiologie de Que´bec (Hoˆpital
Laval) (Pierre Voisine, MD)
NIH Heart Center at Suburban Hospital (Keith A.
Horvath, MD)
Ohio State University Medical Center (Benjamin C.
Sun, MD)
Valley Hospital, Ridgewood, NJ (Alexander Zapolanski,
MD)
Kennestone Hospital, Marietta, Ga (William A. Cooper,
MD)
Data Coordinating Center
International Center for Health Outcomes and Innovation
Research, Mount Sinai School of Medicine (InCHOIR),
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off, PhD)
Study Chair, Co-Chair
Timothy J. Gardner, MD (Chair); Christiana Care Health
System
Patrick T. O’Gara, MD (co-Chair); Brigham and
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National Heart Lung and Blood Institute (Marissa Miller,
DVM MPH (Program Director); Karen Ulisney, MSN,
CRNP (Deputy Program Director)
Canadian Institute of Health Research (Ilana
Gombos, PhD)
National Institute of Neurological Disorders and Stroke
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